Deray G, Khayat D, Jacquiaud C, Bizzari J P, Bourbouze R, Musset L, Jaudon M C, Baumelou B, Jacquillat C, Jacobs C
Department of Nephrology, Hopital Pitié-Salpêtrière, Paris, France.
Cancer Chemother Pharmacol. 1990;26(6):467-8. doi: 10.1007/BF02994102.
The renal hemodynamic and tubular effects of S10036 (fotemustine) were evaluated in seven patients with advanced malignancy. Initial evaluation carried out prior to treatment and repeated 1 day after the first fotemustine infusion and 7 days after the second included clinical, haematological parameters, liver-function tests, and determination of the glomerular filtration rate, renal blood flow and enzymuria. The glomerular filtration rate was 108 +/- 3.7 ml/min before treatment and remained stable after the first (117 +/- 5 ml/min) and second (124 +/- 6 ml/min) fotemustine infusions. Renal blood flow and urinary beta 2-microglobulin and N'-acetylglucosaminidase excretion were also not modified by fotemustine administration. We conclude that fotemustine does not acutely alter renal haemodynamics, nor does it have direct tubular toxicity.
对7例晚期恶性肿瘤患者评估了S10036（福莫司汀）对肾脏血流动力学和肾小管的影响。在治疗前进行初始评估，并在首次福莫司汀输注后1天以及第二次输注后7天重复评估，评估内容包括临床、血液学参数、肝功能检查，以及肾小球滤过率、肾血流量和尿酶的测定。治疗前肾小球滤过率为108±3.7 ml/min，在首次（117±5 ml/min）和第二次（124±6 ml/min）福莫司汀输注后保持稳定。福莫司汀给药后肾血流量、尿β2-微球蛋白和N'-乙酰氨基葡萄糖苷酶排泄也未改变。我们得出结论，福莫司汀不会急性改变肾脏血流动力学，也没有直接的肾小管毒性。
